TP53 and hepatocellular carcinoma: Other studies have shown that the TERT promoter, co-mutation of bromine-containing domain protein 4 (BRD4), and tumor protein P53 (TP53) can also be used as reliable signals to predict mutation risk, thus guiding the selection of the treatment regimen for individualized HCC immunotherapy (16).